$1.86
1.06% yesterday
Nasdaq, Jun 02, 10:00 pm CET
ISIN
US45257L1089
Symbol
IMMP
Sector
Industry

Immutep Ltd Sponsored ADR Stock News

Neutral
GlobeNewsWire
7 days ago
SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable ...
Positive
Seeking Alpha
26 days ago
Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncer...
Neutral
GlobeNewsWire
2 months ago
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:
Neutral
GlobeNewsWire
4 months ago
Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controls Promising new results ...
Positive
Seeking Alpha
4 months ago
Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials withou...
Neutral
GlobeNewsWire
6 months ago
SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. Through the first three...
Neutral
GlobeNewsWire
6 months ago
SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combina...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today